THE NEXT GENERATION OF ANTIBODY-DRUG CONJUGATES

Novel Targeted Therapies with immunomodulatory activity

ANTIBODY-DRUG CONJUGATES (ADCs)

ADCs are targeted therapies that combine monoclonal antibodies, chemically linked to cytotoxic drugs (potent anti-cancer agents).

The importance of developing the best-in-class antibodies

Clinical efficacy of antibody-drug conjugates relies heavily on the binding capabilities and specificity to the tumor antigen of the monoclonal antibody used in the drug conjugate, as well as on the internalization of the ADC construct. Targeted delivery of cytotoxic payloads increases the anti-cancer effect while reducing the exposure of normal tissues and increasing the therapeutic index of the treatment.

CellmAbs has designed novel ADCs using innovative and proprietary antibodies that are cancer-specific but also have immunomodulatory activity, acting in synergy with the cell killing effect of the payload.

The importance of chemistry

Selecting the right linker and payload is critical and impacts the delivery of the drug, as well as the bioavalability and safety of the ADC.

ADDRESSING THE MAIN CHALLENGES OF

ANTIBODY-DRUG CONJUGATES

(ADC’S)

  • Tumor Selectivity and Specificity

    CellmAbs antibodies have shown to have an unprecedented binding capability and tumor selectivity, targeting a subset of cancer-specific antigens.

    Studies have shown that our antibodies bind with high specificity, selectivity, and affinity to primary cancers and metastatic human tissues and do not bind to normal/healthy human tissues.

  • Tumor Heterogeneity

    Our unique understanding of the tumor micro-environment and target expression uses tumor heterogeneity in our favor.

    By developing ADCs with different profiles, we can target high antigen expression cancers with very toxic payloads maintaining the safety profile while targeting cancers with intermediate to low target expression, taking advantage of the bystander-killing effects of the payloads of some of our ADCs.

  • Patient Selection and Stratification

    We have developed precision oncology strategies to understand antigen expression and tumor response, improving clinical outcomes.

    Precision oncology is based on identifying and using cancer biomarkers in the selection and treatment of patients with cancer.

  • Internalization

    We have developed antibodies with a very high internalization profile, suitable for delivering a group of selected well-established and effective payloads to the Tumor Micro-Environment in Solid Tumors.

ADCs WITH DUAL ACTIVITY

Our ADCs use antibodies that have shown efficacy in tumor growth inhibition in vivo assays. 

CBS antibodies have shown to have immunomodulatory activity by restoring Dendritic Cell maturation, leading to T-cell activation while reducing tumor cell growth and proliferation.